Actually, ICIs targeting the programmed cell death 1 and programmed cell death‐ligand 1 (PD‐L1) pathway, such as nivolumab, pembrolizumab, atezolizumab, and durvalumab monotherapy or in combination with chemotherapy have been shown to prolong the survival of patients with SCLC with manageable toxicity profile.3 Here, CD274 is linked to small cell lung carcinoma.